Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 1Polycystic Ovary Syndrome 1Hyperandrogenism 1Anovulation 1Adenocarcinoma, Follicular 1

Interventions

Iodine-131 5lenvatinib 3X-Rays 3Thyrotropin Alfa 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Sunitinib 2Specimen Handling 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1selpercatinib 1pembrolizumab 1pazopanib 1durvalumab 1cobimetinib 1cabozantinib 1Vemurafenib 1Thyrotropin 1Thalidomide 1Surgical Procedures, Operative 1Sorafenib 1Sodium Iodide 1Semaxinib 1Photons 1Photochemotherapy 1Phantoms, Imaging 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Follicular × Glycoprotein Hormones, alpha Subunit × Clear all
NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡